SLU-PP-332 Supplier China: Small-Molecule COA Guide

Correct the product class in the controlled specification

State SLU-PP-332, the authoritative chemical name or molecular reference, CAS number, molecular formula and molecular weight where confirmed, physical form, target quality attributes, nominal 5mg content, quantity and RUO status. Explicitly classify it as a small-molecule research compound. Do not request an amino-acid sequence or accept a supplier record that describes it only as a peptide. Map spelling variants such as SLU PP 332 to one approved identity and require that identity on the quote, COA, analytical sample, label and packing list.

Check CAS, formula and molecular mass as one identity set

Compare the supplier's CAS number, molecular formula, expected molecular mass and structural representation against the buyer-approved reference. These fields should describe the same material and form. Record salts, solvates or other form differences separately because they can alter expected mass and quantitative interpretation. Treat inconsistent identifiers as a blocking exception rather than correcting the COA informally. A marketplace title, product photograph or neighboring peptide category cannot resolve a disagreement among structure, formula, mass and analytical target.

Review HPLC and MS evidence within method scope

Require complete batch-linked chromatographic and molecular-identity files. Check sample identifier, expected and observed molecular information, complete chromatogram, integration, method conditions or reference, test dates, report number and authorization. Ask how the tested sample connects to bulk material and finished 5mg units. HPLC can support chromatographic purity but does not establish every structural feature or exact quantity. MS can support mass identity but cannot alone prove purity, isomeric structure, content or all impurity risks. Record the scope and limitations of each result.

Verify 5mg content independently from headline purity

Ask which quantitative method or controlled filling record supports the 5mg statement and what tolerance applies. Clarify whether the nominal amount means net SLU-PP-332 or total powder including water, residual solvent or formulation components. Keep chemical identity, chromatographic purity, assay and finished-unit content in separate columns. Reconcile bulk issued, units filled, rejects and remaining material where applicable. Compare suppliers by total documented target compound and equivalent analytical scope, not by vial price or an unsupported 99-percent claim.

Reject peptide-specific handling claims without evidence

Do not copy handling or solubility instructions from peptide products. Obtain a supplier-supported specification and SDS for the exact material and approve only research handling statements that are traceable to the offered form and packaging. Require labels with product, strength, lot and RUO wording. Map seller, synthesis, testing, filling, release, stock and shipping roles, confirm MOQ and document timing, and require notification before changes to identity, form, test methods, packaging or other approved conditions. Review each new lot independently.

Build one comparable wholesale RFQ matrix

Send every candidate the same fields: controlled identity, strength, vial count, total material, target purity or composition, identity method, quantitative-content basis, offered lot, testing status, packaging, documents, MOQ, lead time and shipping term. Mark missing answers as exceptions instead of filling gaps with assumptions. Separate testing, setup, customization and transport costs from recurring unit price. A standardized matrix gives scientific, purchasing and quality reviewers one auditable record and prevents an incomplete offer from appearing cheaper simply because it describes less work.

Apply a batch-focused quality-control review

Define every required attribute, acceptance criterion, method and record before purchase. Use the quality-control framework to connect each supplier claim to evidence and its method scope. Check sample identifiers, dates, report numbers, units and lot relationships across the complete reports. Batch-specific evidence is more decision-useful than a representative certificate. Preserve original files, record revisions and investigate contradictions before approving shipment. Where risk warrants, arrange independent testing under a documented sampling and custody plan.

Create a documentation gate before dispatch

List the required batch COA, analytical attachments, SDS, specification, supported storage statement, label proof, invoice and packing list in the RFQ and purchase order. Reconcile product, strength, lot, quantity and revision across records with the documentation guide. Require replacement documents when the offered lot changes. The importer remains responsible for current destination requirements. Research-use wording improves clarity but cannot guarantee customs entry or replace destination-specific legal and broker review.

Verify supplier and batch ownership

Document the legal seller, manufacturing site, analytical laboratory, filling or packaging site, inventory owner, release authority and dispatch entity for the exact SKU. A trading or coordination company can work with qualified partners, but roles and accountability must be transparent. Ask who owns the batch record, authorizes release, handles deviations and provides corrective action. Require advance notification when a critical party changes. Business-registration evidence supports identity but does not replace technical qualification of the offered lot.

Plan logistics and receiving controls

Confirm dispatch location, carrier, shipping term, packaging configuration and realistic production, release and transit windows. Reject guarantees of customs clearance or misleading declarations. On receipt, document package condition, seals, product, strength, lot and quantity, then connect internal inventory to the supplier batch. Store according to the applicable approved specification and quarantine unexplained damage, label conflicts, quantity differences or excursions until a documented quality decision is completed.

Use actual performance for repeat-order approval

A controlled evaluation order should use the same specification and evidence expectations planned for wholesale scale. Assess document accuracy, packaging, delivery time, communication and corrective response. Update a supplier scorecard from observed performance rather than catalog breadth or claims. For every new lot, repeat the batch review and approve current documents before dispatch. Require notification before changes to material specification, manufacturing, testing, filling, labels, packaging or other buyer-approved conditions.

Related products and same-category guides

• SLU-PP-332 5mg
• AICAR Supplier Guide
• HPLC and MS Testing Guide

Frequently asked questions